ERTRACER SOLUTION FOR INJECTION
Active substance(s): FLUDEOXYGLUCOSE (18-F) / FLUDEOXYGLUCOSE (18-F) / FLUDEOXYGLUCOSE (18-F)
ERtracER Solution for Injection
Read all of this leaflet carefully before you are administered this medicine because it
contains important information for you.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your referring doctor or the specialist in Nuclear
Medicine who will supervise the procedure.
If you get any side effects, talk to your referring doctor or the specialist in Nuclear
Medicine. This includes any possible side effects not listed in this leaflet.
What is in this leaflet:
1. What ERtracER is and what it is used for.
2. What you need to know before ERtracER is administered.
3. How ERtracER is used.
4. Possible side effects.
5. How ERtracER is stored.
6. Contents of the pack and other information.
1. What ERtracER is and what it is used for.
This medicine is a radiopharmaceutical product for diagnostic use only.
The active substance contained in ERtracER is fludeoxyglucose (18F) and is designed for the
capture of diagnostic images of some parts of your body.
Once a small amount of ERtracER has been injected, medical images that are obtained with
a special camera will enable the doctor to capture images and see where your illness is or
how it is progressing.
Your body contains millions of living cells. All the cells use sugar (glucose) for energy. When
you have certain medical conditions, some parts of your body will use more glucose than
normal. Doctors use this change in the amount of glucose used to help identify and pinpoint
the site of certain medical conditions.
When ERtracER is given to you, a small amount of radioactive glucose spreads around your
body and reaches the areas where glucose is being used the most.
By using a special camera, known as a PET scanner or a gamma-camera, pictures (images) of
the radiation coming from the ERtracER let your doctor ‘see’ where the radioactive glucose
is being used the most. He/she can then use this to help identify (diagnose) and pinpoint
sites where you have a particular medical condition.
This diagnostic medicine can be used to help find out:
i. Whether you have certain brain conditions such as epilepsy, dementia (Alzheimer’s),
infections or tumours.
ii. If you have an abnormality of the heart.
iii. If you have a certain type of cancer and where it is located.
iv. How well your cancer treatment is working.
2. What you need to know before ERtracER is used
ERtracER must not be used
- if you are allergic to fludeoxyglucose (18F) or any of the other ingredients of this
medicine (listed in section 6).
Warnings and Precautions
Talk to your doctor or the specialist in Nuclear Medicine before being administered
If you are a diabetic and your diabetes is currently not controlled the test may not give
the right result if you have high blood sugar. Also read the sections overleaf on using
other medicines and using ERtracER with food and drink.
If you have an infection or an inflammatory disease
If you are affected by kidney problems
Inform your doctor or the specialist in Nuclear Medicine in the following cases:
- If you are pregnant or believe you may be pregnant
- If you are breast-feeding
Before administration of ERtracER you should:
- drink plenty of water before the start of the examination in order to urinate as often as
possible during the first hours after the study
- avoid all non-essential physical activity
- be fasting for at least 4 hours
Children and adolescents
Please talk to your referring doctor or the specialist in Nuclear Medicine if you are less than
18 years old.
Other medicines and ERtracER
Tell your doctor or the specialist in Nuclear Medicine who will supervise the procedure if
you are taking, have recently taken or might take any other medicines, since they may
interfere with your doctor’s interpretation of the images:
any medicine that may induce a modification of the blood sugar rate (glycaemia), such
as medicines that have an effect on inflammation (corticosteroids), medicines against
convulsions (valproate, carbamazepine, phenytoin, phenobarbital), medicines affecting
the nervous system (adrenaline, noradrenaline, dopamine),
medicines used to increase the production of blood cells
ERtracER with food and drink
You should be fasting for at least 4 hours before the administration of the product. You
should drink plenty of water and avoid drinking liquids containing sugar.
Your doctor or the specialist in Nuclear Medicine will measure your blood sugar before
administering the product; indeed a high blood glucose concentration (hyperglycaemia) can
make the doctor’s interpretation more difficult.
Pregnancy and breast-feeding
You must inform the nuclear medicine doctor before the administration of ERtracER if there
is a possibility you might be pregnant, if you have missed your period or if you are breastfeeding.
When in doubt, it is important to consult your doctor or the specialist in Nuclear Medicine
who will supervise the procedure.
If you are pregnant
The doctor or specialist in Nuclear Medicine will only administer this product during
pregnancy if a benefit is expected which would outweigh the risks.
If you are breast-feeding:
You must stop breast-feeding for about 12 hours after the injection and the maternal milk
pumped must be discarded.
Resuming breast-feeding should be in agreement with the doctor or specialist in Nuclear
Medicine who will supervise the procedure.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a
baby, ask your doctor or the specialist in Nuclear Medicine for advice before you will be
administered this product.
Driving and using machines
It is considered unlikely that ERtracER will affect your ability to drive or to use machines.
ERtracER contains sodium
This product may contain more than 1 mmol of sodium (23 mg). You should take this into
account if you are on a low sodium diet.
3. How will ERtracER be used
There are strict laws on the use, handling and disposal of radiopharmaceutical products.
This product will only be used in special controlled areas. This product will only be handled
and give to you by people who are trained and qualified to use it safely. These persons will
take special care for the safe use of this product and will keep you informed of their actions.
The doctor or specialist in Nuclear Medicine supervising the procedure will decide on the
quantity of ERtracER to be used in your case. It will be the smallest quantity necessary to
get the desired information.
The quantity to be administered usually recommended for an adult ranges from 100 to
400 MBq (depending on the patient’s body mass, the type of camera used for imaging and
the acquisition mode). Megabecquerel (MBq) is the unit used to express radioactivity.
Use in children and adolescents
In case of use in children and adolescents, the quantity to be administered will be adapted
to the child’s weight.
Administration of ERtracER and conduct of the procedure
ERtracER is administered intravenously.
One injection is sufficient to conduct the test that your doctor needs.
After injection you will need to be completely at rest, without reading or talking. Also, you
will be offered a drink and asked to urinate immediately preceding the procedure.
While the pictures are being taken, you will need to be completely at rest. You should not
move or talk.
Duration of the procedure:
Your doctor or specialist in Nuclear Medicine will inform you about the usual duration of the
procedure. ERtracER is administered as a single injection in a vein, 45-60 minutes before the
imaging acquisition takes place. The imaging acquisition with the camera lasts 30 to 60
After administration of ERtracER, you should:
- avoid any close contact with young children and pregnant women for the 12 hours
following the injection
- urinate frequently in order to eliminate the product from your body
If you have been given more ERtracER than you should
An overdose is unlikely because you will only receive a single dose of ERtracER precisely
controlled by the nuclear medicine doctor supervising the procedure. However, in the case
of an overdose, you will receive the appropriate treatment. In particular, the doctor or
specialist in Nuclear Medicine in charge of the procedure may recommend that you drink
abundantly in order to facilitate the elimination of ERtracER from your body (indeed the
principle way of elimination of this product is renal, in the urine).
If you have any further questions on the use of ERtracER, please ask your doctor or the
specialist in Nuclear Medicine who supervises the procedure.
4. Possible side effects
Like all medicines this medicine can cause side effects, although not everybody gets them.
This radiopharmaceutical product will deliver a low amount of ionising radiation with the
least risk of cancer and hereditary abnormalities.
Your doctor has considered that the clinical benefit that you will obtain from the procedure
with the radiopharmaceutical overcomes the risk due to radiation.
If you get any side effects talk to your doctor or the specialist in Nuclear Medicine. This
includes any possible any possible side effects not listed on this leaflet.
Reporting of Side Effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any
possible side effects not listed in this leaflet. You can also report side effects directly in the
Republic of Ireland via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1
6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: email@example.com or in the
United Kingdom via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard
By reporting side effects you can help provide more information on the safety of this
5. How ERtracER is stored
You will not have to store this product. This product is stored under the responsibility of the
specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance
with the national regulations for radioactive materials.
The following information is intended for the specialist only:
This product must not be used after the expiry date which is stated on the container label.
This product must not be used if there are any visible signs of deterioration (it should be a
clear colourless solution).
Use within four hours of withdrawing the first dose.
6. Contents of the pack and further information
What ERtracER contains
- The active substance is fludeoxyglucose (18F). 1 ml solution for injection contains 11010,000 MBq fludeoxyglucose (18F) at the date and time of calibration.
- The other ingredients are: Water for Injections, Sodium Chloride and Sodium
Dihydrogen Phosphate Dihydrate.
What ERtracER looks like and contents of the pack
The medicine, ERtracER, is a clear, colourless liquid that is provided in a small glass vial with
a rubber stopper and a cap. The activity per vial ranges from 110 MBq to 50,000 MBq at the
date and time of calibration.
Marketing Authorisation Holder and Manufacturer:
The MA holder and manufacturer:
M2i Ltd, Blackrock Clinic, Blackrock, Co. Dublin, Republic of Ireland.
Tel: 00353 1-206-4266. E-mail: firstname.lastname@example.org
This leaflet was last revised in November 2014
Is this leaflet hard to see or read?
Phone 00 353 1 206 4266 for help
Source: Medicines and Healthcare Products Regulatory Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.